Marusenko Irina Mikhaylovna | Petrozavodsk State University, Lenina pr., 33, Petrozavodsk, 185910, imarusenko@yandex.ru |
Vezikova Natalia Nikolaevna | Petrozavodsk State University, Lenina pr., 33, Petrozavodsk, 185910, vezikov23@mail.ru |
Barysheva Olga Yuryevna | Petrozavodsk State University, Lenina pr., 33, Petrozavodsk, 185910, imarusenko@yandex.ru |
rheumatoid arthritis biological therapy genetically engineered biological preparations infliximab rituximab |
The article is devoted to one of the topical problems of modern medicine – the treatment of rheumatoid arthritis with the use of genetically engineered biological agents in the Republic of Karelia. Here we discuss data on the disease prevalence in the world and in Russia, describe main approaches to the treatment of rheumatoid arthritis and the role of genetically engineered biological agents in basic therapy of the disease. An overview of drugs included in the group of genetically engineered biological agents, their targets and effectiveness is presented. In Karelia, the Center of anticytokine therapy was established in 2007 on the basis of V.A. Baranov Republic Hospital of the Ministry of Healthcare. We report original data on the number of patients with rheumatoid arthritis or juvenile rheumatoid arthritis who were administered genetically engineered biological drugs since 2007 to 2013. We analyzed therapeutic indications for administration of genetically engineered biological drugs and efficacy of infliximab and rituximab considered as the most frequently used drugs. The data on the incidence and severity of side effects of these drugs are performed as well. We conclude that genetically engineered biological therapy is a safe and effective treatment option for patients with rheumatoid arthritis or juvenile rheumatoid arthritis, which, unfortunately, can be used only for a limited number of persons because of its expensiveness. |